ArticleBlood advances2017

Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors.

Midori Shima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.